PDCD1 and nonpapillary renal cell carcinoma: ICIs that block PD-1, PD-L1, and CTLA-4, such as nivolumab, pembrolizumab, and ipilimumab, have shown clinical benefit in metastatic ccRCC by reactivating T cells and partially reversing immune suppression [10,11].